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Practice points
• Twenty-three years after the introduction of minimally invasive sentinel lymph node staging for melanoma,
sentinel lymph node biopsy (SLNB) was performed in 65% of the eligible Dutch patients with melanoma in 2016.
• In The Netherlands, large regional differences persist in the performance of SLNB in stage IB–II melanoma, with
74% in the northeast compared with 56% in the rest of The Netherlands (p < 0.01).
• SLNB is less often performed in elderly patients and in those with head-and-neck melanoma.
• In The Netherlands, socioeconomic status no longer affected use of SLNB during the time period studied.
• Until promising noninvasive procedures and effective therapies emerge in the field of melanoma, further
implementation of SLNB and adherence to melanoma guidelines, in accordance with the current eighth
American Joint Committee on Cancer staging in melanoma, are indicated.
Aim: To investigate implementation of the seventh American Joint Committee on Cancer melanoma stag-
ing with sentinel lymph node biopsy (SLNB) and associations with socioeconomic status (SES). Patients &
methods: Data from The Netherlands Cancer Registry on patient and tumor characteristics were analyzed
for all stage IB–II melanoma cases diagnosed 2010–2016, along with SES data from The Netherlands In-
stitute for Social Research. Results: The proportion of SLNB-staged patients increased from 40% to 65%
(p < 0.001). Multivariate analysis showed that being female, elderly, or having head-and-neck disease re-
duced the likelihood of SLNB staging. Conclusion: SLNB staging increased by 25% during the study period
but lagged among elderly patients and those with head-and-neck melanoma. In The Netherlands, SES no
longer affects SLNB staging performance.
First draft submitted: 2 October 2019; Accepted for publication: 22 January 2020; Published online:
30 March 2020
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Sentinel lymph node biopsy (SLNB) in patients with American Joint Committee on Cancer (AJCC) stage IB–II
melanoma was introduced in The Netherlands in 1996. The Dutch Society of Surgical Oncology and several
regional working groups of The Netherlands Comprehensive Cancer Organization disseminated the SLNB staging
model in The Netherlands.
Prospective studies, such as the Multicenter Selective Lymphadenectomy Trial (MSLT)-I and the more recent
MSLT-II, demonstrated the staging and prognostic value of SLNB for stage IB–II melanoma [1–4]. Most patients are
pleased with the outcomes of this minimally invasive staging procedure that yields good information with limited
negative effects on quality of life [5,6]. MSLT-I results showed that SLNB is a low-morbidity procedure for staging
the regional nodal basin in early melanoma and that complete lymph node dissection (CLND) is associated with
lower morbidity compared with therapeutic lymph node dissection [2–4,7]. MSLT-II indicated an association of
CLND with increased regional disease control. However, this benefit did not involve increased melanoma-specific
survival compared with patients managed with positive SLNB and regular ultrasonography of the lymph node
basin, with therapeutic lymph node dissection in case of regional recurrence [4].
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Interferon (IFN) has been extensively studied in different regimens (high, intermediate, low dose, pegylated IFN,
with or without induction phase, shorter and longer maintenance dose) in 15 adjuvant trials for advanced melanoma,
but with a minimal effect overall [8]. The prognosis of stage III and IV melanoma has improved considerably in the
last 10–15 years through targeted therapy with BRAF inhibitors (dabrafenib and vemurafenib) in BRAF-mutated
disease, or with MEK inhibitors (trametinib and cobimetinib) and immunotherapy with the immune checkpoint
inhibitors anti CTLA-4 antibody (ipilimumab) and anti-PD1 antibodies (nivolumab and pembrolizumab) [9].
In addition to these new, effective systemic therapies, two new intralesional therapies are in current trials. One
is intralesional local melanoma treatment with talimogene laherparepvec, an oncolytic virus therapy. The other
involves chemoablation with intralesional Rose Bengal, a small-molecule oncolytic immunotherapy [10,11]. Either
of them, used for the treatment of in-transit metastases or metastatic disease, may also enhance the patient immune
system. Targeted and/or immunotherapy treatment may improve disease-free and overall survival for patients with
stage III and IV melanoma. Optimal staging of clinical stage IB–II melanoma is therefore indicated to identify
patients with high-risk stage IIIA disease who might also benefit from these new therapies.
Seventeen years after the introduction of SLNB staging for melanoma, this procedure was performed in less
than 50% of all eligible patients in The Netherlands. Considerable practice variation has been observed in SLNB
procedures among the eight cancer regions of the Comprehensive Cancer Organization, ranging from 22.5 to
56.5% [12,13]. The revised Dutch melanoma guideline of 2012 advised SLNB staging for stage IB–II melanoma.
However, in 2014, only 25% of melanoma-treating specialists in The Netherlands endorsed the need for SLNB for
regional staging of stage IB–II disease. Residents endorsed at a higher rate, but still at only 44% [14]. Furthermore,
in patients with head-and-neck melanoma, older patients and patients with a low socioeconomic status (SES),
SLNB was less frequently performed. It was used more often in patients with T3 melanomas and those diagnosed
with melanoma in a university hospital [12,13,15].
The aim of the current study was to update information about the performance of SLNB in The Netherlands in
clinical stage IB–II melanoma after implementation of the seventh edition of the AJCC staging manual in 2010 [16],
which included sentinel lymph node staging. This aim was selected because high-risk patients might benefit from
new systemic therapies and to allow comparison of these results with previous reports from The Netherlands among
cancer regions and provinces and investigation of the role of SES in SLNB implementation.
Methods
Study population
This study included all patients with localized melanoma stage IB–II diagnosed 2010–2016. Data were retrieved
from The Netherlands Cancer Registry, embedded within The Netherlands Comprehensive Cancer Organiza-
tion [17]. This population-based registry relies on notification by the automated nationwide network and registry
of histopathology and cytopathology in The Netherlands and is complemented by other sources such as a na-
tional registry of hospital discharge and radiotherapy institutes. Data collection was conducted according to the
declaration of Helsinki ethical principles for medical research involving human subjects [18].
After notification, fully trained registrars routinely collected data from pathology reports and patient files in all
Dutch hospitals. Data were collected on patient and tumor characteristics, such as age, sex, tumor localization of
the primary melanoma and tumor stage. Information about the performance and outcome of SLNB was retrieved
from the medical records. Patients with clinically suspicious or palpable lymph nodes, distant metastases and/or
a history of lymph node dissection were excluded. SES scores were assigned to different postal code areas by The
Netherlands Institute for Social Research and calculated based on income, employment and level of education [19].
Calculated scores give an estimate of the SES in the particular postal code area where a patient resides. Calculated
SES scores are divided into five groups: SES = 1 (low) to SES = 5 (high).
To render the data from this study comparable to those from previous studies with respect to the SLNB staging
in The Netherlands, the northeastern part of the country was compared with the rest of The Netherlands, as were
the eight cancer regions and provinces [12,13]. This approach made it possible to investigate the role of the Dutch
Society of Surgical Oncology and several regional working groups of The Netherlands Comprehensive Cancer
Organization in the dissemination of the SLNB approach.
Statistical analysis
Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., NC, USA). Patient characteristics
were compared between the northeastern provinces and the rest of The Netherlands using Chi-square or Mann–
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Figure 1. Trend in the proportion of sentinel lymph node biopsy performed per year of diagnosis in all patients
with stage IB–II melanoma in The Netherlands; comparison among topographical regions.
Whitney U tests (the latter with nonnormally distributed data). Also, patient characteristics from SLNB-positive
and -negative cases were compared. Multivariable logistic regression analysis was performed to estimate the odds for
undergoing SLNB. Values were adjusted for factors that could influence the decision to perform SLNB (e.g., region,
age, primary lesion location, Breslow thickness, pathological stage of primary tumor, SES). p < 0.05 was considered
statistically significant.
Results
During the study, a total of 19,100 patients with stage IB–II melanoma were registered (9344 males (49%) and
9756 females (51%)). SLNB was performed in 9163 (48%) overall. The proportion of melanoma patients who
received SLNB increased, however, from 40% in 2010 to 65% in 2016 (Figure 1). The procedure was performed
significantly more often in the northeastern part of The Netherlands compared with the rest of the country
(p < 0.01; Table 1 & Figure 1). An overview of the percentage SLNBs performed in each province in The
Netherlands is presented in Figure 2.
Of the 9163 patients who underwent SLNB, positive nodes were found in 1877 patients (20%; Table 2). No
differences were found in patient or tumor characteristics and sentinel node positivity between the northeastern
part of The Netherlands and the rest of the country (data not shown).
Median age at diagnosis in the SLNB group was 58 (interquartile range [IQR], 47–68) years, compared with
67 (IQR: 53–78) years in the group that did not undergo SLNB (p < 0.001). Tumors in the SLNB group were
thicker (median Breslow thickness, 1.7 [1.2–2.8] mm, compared with 1.3 [0.9–2.7] mm in the non-SLNB group
[p < 0.01]), and tumor stage at diagnosis was significantly higher (p < 0.01). Most primary melanomas were
located on the trunk (37%), followed by the lower limb (27%), upper limb (21%), and head-and-neck region
(15%). Significantly fewer SLNBs were performed among patients with melanomas located in the head-and-neck
area (p < 0.01; Table 1). Figure 2 presents an overview by province of the percentage of SLNBs performed in
future science group www.futuremedicine.com
Research Article Deckers, Louwman, Kruijff & Hoekstra
Table 1. Characteristics of all patients with stage IB–II melanoma in The Netherlands, diagnosed 2010–2016, comparison
between groups (sentinel lymph node biopsy [yes/no]).
SLNB performed No SLNB performed Total p-value
n % n % n %
Gender 0.3¶
– Male 4518 49 4826 49 9344 49
– Female 4645 51 5111 51 9756 51
Age (years) at diagnosis <0.01¶
– 15–29 392 4 229 2 621 3
– 30–44 1489 16 1001 10 2490 13
– 45–59 3120 34 2258 23 5378 28
– 60–74 3278 36 3254 33 6532 34
– 75 884 10 3195 32 4079 21
Median age (years) (Q1–Q3) 58 (47–68) 67 (53–78) 62 (49–73) <0.01#
Location primary <0.01¶
– Head/neck 590 6 2269 23 2859 15
– Trunk 3737 41 3296 33 7033 37
– Arm 2017 22 2048 21 4065 21
– Leg 2814 31 2308 23 5122 27
– Overlapping 5 0 16 0 21 0
Breslow thickness (mm) <0.01¶
– 1 1155 13 3307 33 4462 23
– 1–2 4352 47 2983 30 7335 38
– 2–3 1710 19 1136 11 2846 15
– 3–4 808 9 635 6 1443 8
– 4 1020 11 1421 14 2441 13
– Unknown 118 1 455 5 573 3
Median Breslow thickness (Q1–Q3) 1.7 (1.2–2.8) 1.3 (0.9–2.7) 1.5 (1.1–2.75) <0.01#
pT <0.01¶
– 1B 1132 12 3254 33 4386 23
– 2 4503 49 3099 31 7602 40
– 3 2539 28 1764 18 4303 23
– 4 952 10 1372 14 2324 12
– X 37 0 448 5 485 3
SES 0.2¶
– 1 (low) 1560 17 1712 17 3272 17
– 2 1729 19 1843 19 3572 19
– 3 1877 20 2100 21 3977 21
– 4 1876 20 2109 21 3985 21
– 5 (high) 2121 23 2173 22 4294 22
Region† <0.01¶
– Northeastern part‡ 2044 22 1386 14 3430 18
– Rest § 7119 78 8551 86 15,670 82
– Total 9163 48 9937 52 19,100 100
Data are displayed as n (%) or median (interquartile range).
†Topographic region in The Netherlands.
‡Northeastern part (Groningen, Friesland, Drenthe and Overijssel).
§Rest of the provinces in The Netherlands.
¶ 2-test,
#Mann–Whitney U test, significant p-values in bold (p  0.05).
pT: Pathological primary tumor stage; Q1–Q3: Interquartile range; SES: Social economic status; SLNB: Sentinel lymph node biopsy.
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Figure 2. Percentages of sentinel lymph node biopsies per province in The Netherlands; comparison among
different anatomical locations of the primary melanoma.
melanomas located in the head-and-neck region, trunk and limbs. No significant differences in SES were found
between the SLNB and non-SLNB groups (p < 0.2; Table 1).
After adjustment for sex, age, tumor location, Breslow thickness, SES and tumor stage, multivariate analysis
showed that SLNBs were more often performed in the northeastern part of The Netherlands (odds ratio [OR],
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Table 2. Sentinel lymph node biopsy positivity in Dutch patients with melanoma between 2010 and 2016, by
topographical region in The Netherlands (n = 9163).
Northeastern part† Rest‡ Total p-value
n % n % n %
SLNB p = 0.7§
Negative 1595 78 5598 79 7193 79
Positive 425 21 1452 20 1877 20
Not
found/unknown
24 1 69 1 93 1
2044 22 7119 78 9163 100
Data are displayed as n (%).
†Northeastern part (Groningen, Friesland, Drenthe and Overijssel).
‡Rest of the provinces in The Netherlands.
§χ 2-test, significant p-values in bold (p  0.05).
SLNB: Sentinel lymph node biopsy.
2.2; 95% confidence interval, 2.01–2.41; Table 3). Females were less likely to undergo SLNB (OR: 0.9; 95% CI:
0.84–0.96; p < 0.05), and SLNB rates decreased with increasing age. Patients with head-and-neck melanomas
underwent SLNBs less often (head/neck vs limb: OR: 0.24; 95% CI: 0.21–0.27; p < 0.05). SLNB was performed
slightly more often among patients from a high SES class (score >5) when compared with low SES (OR, 1.2; 95%
CI: 1.04–1.29; p < 0.05; Table 3).
Discussion
This study showed that in 2016, a quarter of a century after its introduction, SLNB was performed in only 65% of
eligible Dutch patients with melanoma. In females, elderly patients and those with head-and-neck melanoma, the
staging procedure was performed even less frequently. However, SES no longer significantly affected the likelihood
of SLNB staging, a change from the association before 2010 [12].
The fourth revision of the Dutch melanoma guidelines published in 2004 advised using SLNB in patients with
stage IB or higher melanoma who wanted to be optimally informed about their prognosis. The SLNB staging
procedure was therefore not part of the standard workup of patients with clinical stage IA-II melanoma. Since
2004, the percentage of SLNBs performed in cases of melanoma increased in The Netherlands from 24% to 55%
in 2011 [12,13].
The 5th revision of the Dutch melanoma guideline in 2012, based on the seventh edition of the AJCC staging
manual that went into effect in 2010 [16], advised SLNB for stage IB–II melanoma and discussed the potential
benefits and drawbacks of CLND in case of sentinel node positivity. Recently, effective adjuvant targeted and
immune systemic therapies for stage III melanoma have become available. Therefore, adequate staging is even more
important, emphasizing the need for insight into the current application of SLNB in The Netherlands.
Large regional differences persist in the use of SLNB in stage IB–II melanoma. Melanoma guidelines are more
often met in academic centers [20]. In the Northeast, the percentage was in 74% in 2016, compared with 56%
in the rest of The Netherlands (p < 0.01). These results are promising and in keeping with the trend in the
northeast, but higher percentages of SLNB performance should be feasible. The current 65% rate of SLNBs is
comparable to previously reported percentages in the USA, from 47% to 60% [21–24]. However, the percentage of
SLNB performed in melanoma remains lower than the almost 80% rate in breast cancer [25]. An explanation might
be that in melanoma, physicians who perform the diagnostic excision and re-excision (if indicated) lack the surgical
skills or opportunity to perform SLNB. Another reason might be that physicians found no indication for SLNB
based on MSLT-II results, because it is only a diagnostic procedure and no longer a therapeutic intervention.
SLNB also can be applied without a good basis. A recent Dutch study showed that use of SLNB in noneligible
melanomas according to the Dutch melanoma guidelines was 2.9% [26]. In Germany, the percentage of SLNB
staging for melanoma is 88% [27,28]. An explanation for the high percentage might be that German dermatologists
are ‘melanomologists’ who manage the whole melanoma surgical and systemic treatment in-house [29]. In contrast,
in The Netherlands and the USA, the melanoma health care landscape is more fragmented, divided among surgeons,
dermatologists, plastic surgeons, head-and-neck surgeons, medical oncologists and in The Netherlands, even per
province and cancer region.This mosaic of care might explain the great variation in SLNB uptake not only in The
Netherlands but also in countries like the USA.
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Table 3. The likelihood of performing sentinel lymph node biopsy adjusted for mul-
tiple variables in Dutch patients with melanoma: a multivariate analysis.
OR 95% CI
Region
– Northern Part† 2.20 2.01 2.41
– Rest ‡ Ref.
Gender
– Male Ref.
– Female 0.90 0.84 0.96
Age (years) at diagnosis
– 15–29 Ref.
– 30–44 0.79 0.64 0.97
– 45–59 0.67 0.55 0.82
– 60–74 0.45 0.37 0.54
– 75 0.11 0.09 0.13
Location primary
– Head/neck 0.24 0.21 0.27
– Trunk 0.90 0.80 1.03
– Limb § Ref.
– Overlapping 0.26 0.09 0.70
Breslow thickness (mm)
– 1 Ref.
– 1–2 2.20 1.70 2.90
– 2–3 2.30 1.60 3.30
– 3–4 2.10 1.50 3.10
– 4 2.00 1.40 2.80
– Onbekend 2.60 1.80 3.90
pT
– 1B Ref.
– 2 2.60 2.00 3.30
– 3 3.60 2.50 5.10
– 4 2.20 1.60 3.20
– x 0.20 0.12 0.33
SES
– 1 Low Ref.
– 2 1.02 0.91 1.14
– 3 1.06 0.95 1.18
– 4 1.05 0.94 1.17
– 5 High 1.17 1.04 1.29
Data are displayed as odds ratio with 95% CI.
†Northeastern part (Groningen, Friesland, Drenthe and Overijssel).
‡Rest of the provinces in The Netherlands,
§Limb (lower and upper extremity).
Significant odds ratios in bold (p  0.05).
OR: Odds ration; pT: Pathological tumor stage; Ref.: Reference; SES: Socioeconomic status.
Age and melanoma located in the head-and-neck region remain important predictors of whether to perform
SLNB. As in this study, an investigation in the general US population found noncompliance with National
Comprehensive Cancer Network melanoma guidelines on SLNB for elderly patients and for melanoma located in
the head and neck [20,24,30]. With melanoma, as for breast cancer, comorbidity could be a limiting factor in whether
or not to perform SLNB. It is also possible that elderly patients, their family, caregivers and treating physicians
decide on a more conservative treatment approach balanced against an existing shorter life expectancy.
future science group www.futuremedicine.com
Research Article Deckers, Louwman, Kruijff & Hoekstra
Performance of SLNB in women was less likely in The Netherlands, although median Breslow thickness was
1.40 (IQR: 1.0–2.5) mm in women compared with 1.70 (IQR: 1.1–3.0) mm in men. This finding of lower rates
of SLNB in women is remarkable because it was adjusted for other factors (e.g., age, primary lesion location,
pathological stage of the primary tumor, Breslow thickness, SES) that could influence the decision to perform
SLNB. Recently, El Sharouni et al. hypothesized two explanations for the differences in sex-specific decision-
making: medical information may be perceived differently, or there may be a clinician-specific sex bias when
approaching and informing female patients [26].
The SLNB positivity rate in this study was 20%, which is comparable to other studies showing between 15 and
22% [28,31,32], as was the location of the primary melanoma [28]. We found that SLNB was performed in 21% of
eligible patients with head-and-neck melanoma in The Netherlands, compared with 17% in a study that included
data up to 2014 [26]. Noncompliance with SLNB recommendations was also found in the U.S. general population
for head-and-neck primary lesions (OR: 2.0; 95% CI, 1.9–2.2) [20,24]. SLNB procedures in the head-and-neck area
are technically difficult, even for experienced surgeons, because of the small incisions, critical anatomical structures
and great variation in atypical and/or multiple drainage sites [33–36]. SLNBs and re-excision procedures of limb and
trunk melanoma can be safely performed under local anesthesia [37]. In contrast, SLNBs for melanoma located in
the head-and-neck region often require general anesthesia that might introduce additional morbidity. These two
reasons might explain the low rates of SLNB performed in patients with head-and-neck melanoma.
In contrast to a previous study performed in The Netherlands, our findings demonstrate that SES no longer
affected SLNB rates during the time period studied [15]. Although SLNB was performed slightly more often among
patients with high SES, it is now routinely performed in The Netherlands for patients with lower SES, as is the
case in Germany, where Livingstone et al. also found no SES influence on SLNB rates [28].
SLNB for melanoma is a minimally invasive staging procedure, accompanied by minimal treatment-related
short- and long-term morbidity [5,7,38–41]. Negative SLNB had no negative effects on quality of life [6]. The quality
of life in Dutch melanoma survivors after axillary or inguinal SLNB, with or without CLND, is even better than
that in a norm group [5]. This suggests that performing SLNB in melanoma patients is a minimal invasive procedure
beneficial for the patients without affecting quality of life.
Compliance with national melanoma guidelines and using an integrated multidisciplinary approach through
case discussions in the melanoma tumor board will improve melanoma-specific, disease-free and overall survival. In
addition, there must be room for shared decision making among treating patients, physicians and caregivers, with
specific assessments of each patient’s ultimate goals of care.
The new, successful treatment of advanced melanoma with targeted and immunotherapies has changed overall
melanoma care in The Netherlands. Each case of advanced melanoma today is discussed at one of 13 melanoma
centers in The Netherlands with respect to (combined) treatment. The promising results achieved with the targeted
and immunotherapies have meanwhile led to increased consultations between hospitals and melanoma centers
with regard to treatment of patients with sentinel node–positive melanoma. The expectation is that further
implementation of SLNB staging will now rapidly take place in The Netherlands.
Limitations
There are several limitations with this study. The reason for offering the patient SLNB or not as a minimally
invasive staging procedure of the regional nodal basin was unknown. Surgeons, plastic surgeons, head-and-neck
surgeons and dermatologists likely differed in reasons for staging a localized melanoma with SLNB, and the patient’s
reasons for accepting or declining a SLNB were not recorded. Also unknown was whether the cases were discussed
in a melanoma tumor board or if there was a consultation with the regional melanoma tumor board of one of
the eight comprehensive cancer centers. Because of general data protection regulations in The Netherlands, the
Comprehensive Cancer Center was unable to retrieve some percentage of SLNBs performed at the various hospitals,
and instead data respective to the provinces were provided.
Conclusion
Twenty-three years after the introduction of minimally invasive sentinel lymph node staging for melanoma, SLNB
was performed in 65% of the eligible Dutch melanoma patients in 2016, although less often in elderly patients,
females and those with head-and-neck melanoma. Age and tumor location in the head-and-neck region might
no longer be exclusion criteria, leaving only severe comorbidity or short life expectancy as contraindications. In
The Netherlands, SES has ceased to be associated with the use of SLNB staging. Until promising noninvasive
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procedures emerge in the field of melanoma staging, further implementation of SLNB and adherence to melanoma
guidelines, in accordance with the current eighth AJCC staging in melanoma, are indicated, especially in view of
the increasingly available effective drug targeted and/or immunotherapy for high-risk melanoma.
Future perspective
In addition to the importance of adequate staging in an era of novel therapies, other advantages should also be
considered. First of all, follow-up after a negative SLNB can be reduced, along with the costs of melanoma follow-up
in 39% of patients, without affecting quality of life [41,42]. Second, a personalized approach will be possible for
sentinel lymph node–positive patients, using a wait-and-see policy and less frequent CLND [9,43,44].
In the optimization of sentinel lymph node staging in a noninvasive manner, ultrasonography is not an effective
substitute for SLNB [45]. However, a promising technology of targeted fluorescence imaging in clinical stage IA-II
melanoma is currently being explored using multispectral optoacoustic tomography (MSOT) (unpublished data).
MSOT provides both anatomical and biological information and has the potential to identify sentinel lymph node
metastatic involvement in patients with melanoma. Thus, when surgery is indicated, removal of only ‘positive’
sentinel lymph node(s) for further pathology examination and mutation analysis is possible.
Two recent studies, DeCOG and MSLT-II, showed that overall survival after a positive SLNB and CLND was
not different from a delayed therapeutic lymph node dissection in case of a regional recurrence [4,46]. Will both
of these negative studies now lead to less frequent offering of SLNB for stage IB–II melanoma according to the
current eighth edition of the AJCC staging? Is SLNB, a minimally invasive staging procedure that provides optimal
staging information with no clear survival benefit, still indicated? With the advent of effective systemic treatments
for melanoma, including targeted or immunotherapies, optimal staging of stage IB–II melanoma appears to be a
sine qua non. In the case of a positive SLNB, a melanoma tumor board should discuss further treatment decisions
based on information about the number of positive SLNBs, nodal basin site and SLNB tumor burden (measured
by maximum diameter of the largest focus or percentage area of the node). Further studies have to be performed to
see if adjuvant systemic treatment for stage IIIA melanoma will improve disease-free and/or overall survival.
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